Real-World data to reveal Ropeginterferon's true impact on blood cancer
NCT ID NCT07282132
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks back at medical records of 150 people with polycythemia vera (a rare blood cancer) who received ropeginterferon alfa-2b. Researchers want to see how well the drug controls the disease over time and what factors help or hinder its effectiveness. The goal is to improve treatment strategies for this chronic condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYCYTEMIA VERA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.